Clinical Trial Supplies Market

The clinical trial supplies market is projected to reach USD 6.3 billion by 2028 from USD 3.9 billion in 2023, at a CAGR of 9.9 % during the forecast period. Integration of big data analytics, AI and blockchain technology in clinical trial supplies with an aim to enhances data integrity, traceability and security, optimize supply chains is likely to propel the growth of clinical trial supplies market. Furthermore, the shift of patients towards personalized medicines have led to the development & demand of customized clinical trial supplies which further likely to boost the growth of the market. Additionally, rise in outsourcing of clinical trials is also contributing to the market growth.

Clinical Trial Supplies Market Size, Dynamics & Ecosystem

To know about the assumptions considered for the study, Request for Free Sample Report

Global Clinical Trial Supplies Market Dynamics

Drivers: Increasing the number of registered clinical trials

According to the World Health Organization (WHO) there has been an increase, in the number of trials registered in 2022 compared to the previous year. Globally 56,793 clinical trials were registered. The United States had the number of trials registered from 1999 to 2022 (168,520) followed by China (94,193) and Japan (63,499). Among the identified phases of development phase II trials accounted for the share at 95,790.

The rise in trials across medical fields such as oncology, neurology and rare diseases is driving up the demand for clinical trial supplies, like logistics, packaging, labeling, storage and distribution. This surge is contributing to market growth

Restraints: High cost of drug development

The significant expense of developing drugs poses an obstacle to the expansion of the clinical trial supplies industry. Pharmaceutical and biotech firms encounter rising costs linked to R&D conducting trials adhering to regulations and managing the supply chain. These expenses involve acquiring trial materials handling logistics and ensuring storage to uphold quality and compliance during the trial phase. Due to these factors, small and mid-sized businesses are likely to invest less in expandable clinical studies, so restricting the need for clinical trial materials.

Opportunities: Growth opportunities in emerging markets

Emerging markets are driving significant increase in the clinical trial supply business. Rising healthcare infrastructure, higher R&D spending, and favourable regulatory environments and growing popularity among these areas for clinical trials define these regions. This tendency is influenced by big patient populations, varied demographics, and cheaper running costs than in developed nations. These advantages are used by pharmaceutical and biotechnological firms to run low-cost studies and cut the length of medication development. Consequently, suppliers of clinical trials are becoming more visible in these fields, thereby boosting global clinical research innovation and driving general market expansion.

Moreover, the expansion of major industry players in the market is probably going to result in profitable development for the clinical trial supplies market. For example, Catelent Inc. (US) acquired Bomi Group to help the expansion in healthcare logistics by raising cold chain capacity in important European and Latin American markets and thus strengthening the company's worldwide presence.

Challenges: The high cost of clinical trials is a major hindrance to the clinical trial supplies market growth

One of the main difficulties of the expansion of the clinical trial supply market is their enormous cost. The growing demand to gather enough clinical data is one of the elements driving up the expenses of clinical studies. Furthermore, offering the comprehensive information about the forthcoming trends and issues that will have a significant impact on the market development in future is this clinical trial supplies market study report. In clinical trial research and development (R&D) expenses were somewhat expensive.

The pharmaceutical and biotechnology companies segment accounted for the largest share in 2022

Based on end users, the clinical trial supplies market is further segmented into, pharmaceutical & biotechnology companies, contract research organizations (CROs), and medical device companies. Rising numbers of clinical trials for chronic illnesses conditions and higher expenditure in medication discovery and development help the pharmaceutical and biotechnology firms to hold the largest share in 2022. Moreover, development in the outsourcing tendency to lower expenses, speed up trial schedules, and provide specialised knowledge is probably going to help the expansion CRO sector.

North America was the largest regional market for Clinical trial supplies market in 2022.

The market is segmented into five major regions namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. North America holds the largest share of the market in 2022; this trend is projected to last throughout the forecast period. Key pharmaceutical and biotechnology businesses supported by a reputable network of Contract Research Organisations (CROs) and clinical trial supply providers are helping North America to be dominant in the clinical trial supplies market.

Over the course of the forecast, Asia Pacific is expected to expand somewhat quickly. One of the elements responsible for the expansion is the increase in clinical trials conducted by biotechnology and pharmaceutical businesses. Moreover, the availability of a sizable and varied patient population, less running costs than in industrialised countries, and strong legislative backing for clinical research is probably going to drive regional market expansion.

Clinical Trial Supplies Market Segmentation & Geographical Spread

To know about the assumptions considered for the study, download the pdf brochure

Key Market Players

Key players in the market include Thermo Fisher Scientific Inc. (US), Marken (US), Catalent, Inc. (US), Eurofins Scientific (France), and PRA Health Sciences (US), Parexel International (MA) Corporation (US), Biocair (UK), AlmacGroup (UK), Piramal Pharma Solutions (India), Sharp Services, LLC (US), PCI Pharma Services (US), Nuvisan (Germany), Lonza Group (Switzerland), OCT Group LLC (US), Corex Logistic Limited (Ireland), Acnos Pharma GMBH (Germany), Clinical Service International (UK), Klifo (Denmark), Clinigen Limited (UK), Ancillare LP (US), N-Side (Europe), ADAllen pharma (UK), Durbin (UK), Recipharm AB (Sweden), IPS Pharma (UK).

Scope of the Clinical Trial Supplies Industry:

This report categorizes the clinical trial supplies market to forecast revenue and analyze trends in each of the following submarkets:

By Service

• Logistics & Distribution
• Storage & Retention
• Packaging, Labelling & Blinding
• Manufacturing
• Comparator Sourcing
• Other Services (Solutions and Ancillary supplies)

By Phase

• Phase I
• Phase II
• Phase III
• Phase IV
• BA/BE Studies

By Type

• Small-Molecules
• Biologic Drugs
• Medical Devices

By Therapeutic Area

• Oncology
• Infectious Diseases
• Neurology
• Metabolic Disorders
• Immunology
• Cardiology
• Genetic Diseases
• Other Therapeutic Areas (Respiratory diseases, dermatological conditions, rare diseases, ENT diseases, and nephrology)

By End User

• Pharmaceutical and Biotechnology Companies
• Contract Research Organisations (CRO's)
• Medical Device Companies

By Region

• North America
  • US
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Switzerland
  • Netherlands
  • Rest of Europe (ROE)
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Singapore
  • Rest of Asia Pacific
• Latin America
  • Mexico
  • Brazil
  • RoLATAM
• Middle East
• Africa

Recent Developments Clinical Trial Supplies Industry

• In July 2023, Thermo Fisher Scientific Inc. (US) and national minority quality forum (NMQF) entered into collaboration with the), which is a non-profit organization dedicated to research and education. This collaboration facilitated through NMQF’s Alliance for Representative Clinical Trials (ARC) in order to increase the inclusion of historically underprivileged patient groups in clinical research.
• In April 2023, Almac Group (UK), introduced the IXRS3 Partnership Network, designed to expedite the creation and deployment of advanced eClinical solutions for biopharmaceutical sponsors.
• In March 2023, Icon Plc (Ireland) and LEO Pharma (Denmark) entered into a strategic partnership in order to enhance LEO Pharma's clinical trial operations, focusing on patient-centricity, cost-efficiency and to strengthen LEO Pharma.
• In August 2022, Marken (US) acquired Bomi Group (Italy) to boost cold chain capacity in key European and Latin American countries and therefore help the expansion in healthcare logistics by strengthening the company's worldwide presence.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst